Head-to-head · WeighScore
BetterMe Rx vs Ilant Health
The verdict
BetterMe Rx takes it — 64.9/100 to 56.8/100.
BetterMe Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. BetterMe Rx offers compounded semaglutide ($199/mo) and tirzepatide ($299/mo) in both injectable and oral daily tablet formats.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | BetterMe Rx | Ilant Health |
|---|---|---|
| WeighScore | 64.9/100 | 56.8/100 |
| Grade | C | C |
| Scorecard rank | #235 | #408 |
| Semaglutide | $199/mo (promotional rate, compounded) | Not disclosed |
| Tirzepatide | $299/mo (promotional rate, compounded) | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #235 · C
Strengths
- LegitScript verified
- All 50 states coverage
- Six named pharmacy partners with phone numbers — exceptional transparency
- Both injectable and oral daily tablet formats for sema and tirz
- Multi-month discounts (3-month and 6-month plans)
Where it loses points
- No formal corporate entity name or address disclosed
- Compounded only — no brand-name options
- Broader platform (HRT, ED, NAD+, Sermorelin, skincare)
- Headline $199/$299 are limited-time SALE prices; regular prices are $249/$349 per month
Graded #408 · C
Strengths
- Value-based, outcomes-driven obesity care model
- Includes GLP-1 medications with transparent drug pricing for sponsors
- Care team of board-certified obesity providers and behavioral specialists
- Dietitians and peer navigators support adherence
- Data-driven stratification targets the right interventions
Where it loses points
- Distributed via employers and health plans, not direct cash-pay
- Individuals generally cannot enroll without sponsor coverage
- No public consumer pricing for GLP-1
- Access gated behind organizational buyers
- Not suited to consumers wanting direct-to-door GLP-1
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.